Prediction of progression-free survival (PFS) adjusted by continuous platinum-free interval (PFI) at fixed timepoints in patients with recurrent ovarian cancer (ROC): Results from OVA-301.

A. Poveda,Bradley J. Monk,Stanley B. Kaye,J.B. Vermorken,Ignace Vergote,I. B. Runnebaum,E. Pujade-Lauraine,Trilok V. Parekh,A. Nieto,J. Gomez,Youn C. Park,Nicoletta Colombo

Prediction of progression-free survival (PFS) adjusted by continuous platinum-free interval (PFI) at fixed timepoints in patients with recurrent ovarian cancer (ROC): Results from OVA-301.

2011

A. Poveda
Bradley J. Monk
Stanley B. Kaye
J.B. Vermorken
Ignace Vergote
I. B. Runnebaum
E. Pujade-Lauraine
Trilok V. Parekh
A. Nieto
J. Gomez
Youn C. Park
Nicoletta Colombo

5067 Background: OVA-301, a randomized, open-label phase III study comparing trabectedin plus pegylated liposomal doxorubicin (PLD) vs. PLD alone in 672 patients with ROC, showed significant and cl...

Keywords:

Oncology
Progression-free survival
Internal medicine
Recurrent Ovarian Cancer
Pathology
Surgery
Medicine
Pegylated Liposomal Doxorubicin
Trabectedin
platinum free
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations